Patient outcomes after therapeutic interchange of dolasetron for granisetron

American Journal of Health-System Pharmacy

Volumn 60, Issue 10, 2003, Pages 1023-1028

  Steiner, MaryAnn ^a   Yorgason, Rossana Zolessi ^b,c   Vermeulen, Lee C ^a,d   Theisen, Joseph ^e  

^a University of Wisconsin Health   (United States)

^b McKay Dee Hospital Center   (United States)

^c UWHC   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e Dean Cancer Clinic   (United States)

Author keywords

Antiemetics; Antineoplastic agents; Dolasetron; Economics; Granisetron; Nausea; Substitution; Toxicity; Vomiting

Indexed keywords

ALPHA2A INTERFERON; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; GEMCITABINE; GRANISETRON; LORAZEPAM; METHOTREXATE; ONDANSETRON; PACLITAXEL; PREDNISONE; PROCHLORPERAZINE; RANITIDINE; RECOMBINANT INTERLEUKIN 2; SEROTONIN 3 ANTAGONIST; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COST CONTROL; DRUG COST; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEOPLASM; OUTCOMES RESEARCH; PATIENT SATISFACTION; PRIORITY JOURNAL; SUBSTITUTION THERAPY;

EID: 0038630861     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.10.1023     Document Type: Article

References (14)

1. Farley PA, Dempsey CL, Shillington AA et al. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapyinduced nausea and vomiting at six cancer centers. Am J Health-Syst Pharm. 1997; 54:2478-82.
2. McCune JS, Oertel MD, Pfeifer D et al. Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study. Ann Pharmacother. 2001; 35:14-20.
3. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999; 4:191-6.
4. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adults and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm. 1999; 56: 729-64.
5. Hesketh PJ. Comparative review of 5HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000; 18:163-73.
6. Lofters WS, Pater JL, Zee B et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997; 15:2966-73.
7. Fauser AA, Duclos B, Chemaissani A et al. Therapeutic equivalence of single oral doses of dolasetron mesylate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. Eur J Cancer. 1996; 32A: 1523-9.
8. Audhey B, Cappelaere P, Martin M et al. A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesylate and granisetron in patients receiving highdose cisplatin chemotherapy. Eur J Cancer. 1996; 32A:807-13.
9. Bollinger KA, Vermeulen LC, Davis SN et al. Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange. Am J Health-Syst Pharm. 2000; 57:368-72.
10. Nelson WW, Vermeulen LC, Geurkink EA. Clinical and humanistic outcomes in GERD patients converted from omeprazole to lansoprazole. Arch Intern Med. 2000; 160:2491-6.
11. Lindley CM, Hirsch JD, O'Neil CV et al. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992; 1:331-40.
12. Vermeulen LC, Windisch PA, Rydman RJ et al. Using a multihospital systems framework to evaluate and establish drug use policy. J Med Syst. 2000; 24: 235-46.
13. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988:8-14.
14. Beckwith CM, Mullin S. Prevention and management of chemotherapy-induced nausea and vomiting, part 1. Hosp Pharm. 2001; 36:67-82.